Karuna Therapeutics Inc (KRTX)

[crudeoil24]

Who cares! > the market consists of traders and investors. Short term trading, and day trading creates liquidity and a healthy market.

[XenaLives]

The link shows the source of the data..

The "folks" making bank would be the Big Boys that own 96%.

Very few little folks involved here.

The fundamentals do not impress me. Anavex has more convincing science and a broader application.

[crudeoil24]

Consult the Big Kahuna, Karuna is mula, mula!

[crudeoil24]

LMAO! Your chart is upside down. Folks making bank with this ATM.

[no shorts]

Ya, would have lost on that one. Still cant go long though. Figure it will pull back soon

[cjstocksup]

KRTX was a more than 4 bagger runner for me this week and congrats to the rest who made money here. We will see in the days ahead if it holds $120.00 and $100.00 but it was sure fun frying shorts non stop for the past 2 days!

[TheFinalCD]

this undoubtedly is one for the record books

Im sure some went short on that offering

they got ran over with a truck

[TheFinalCD]

Im fortunate that TDA wouldnt let me short @ $90

[Nebuchadnezzar]

yea, this is insane

[RKTraderx]

Unreal!

[pennyking130]

Holy freaking sh*t!!!!!!!!!!!!

[VMB-1]

~Something was up when it didn't even Flinch after the Offering.. 250? =D

[europtiger]

Dindinding 160$ now

Fun to watch

[cjstocksup]

And yesterday the shorts were calling for KRTX to go down to $40.00. They got screwed all the way to $148.00 so far.

[europtiger]

140 now lol

[europtiger]

You Lucky there is no Options ;)

[cjstocksup]

I knew the KRTX shorts would continue to get screwed when yesterday I called for $100.00 to hit then today when we held so well in the $90's. That was a clear sign of another squeeze and I love that we squeezed them over $130.00.

[VMB-1]

~1.30 Defying the Odds!

[cjstocksup]

I love it. KRTX over $100.00 today!

[VMB-1]

~Crazyyyyyy =D

[XenaLives]

This is a recycled drug which is being re-engineered to control side effects.

CNS Drug Rev. 2003 Summer;9(2):159-86.


Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR1, Peters D, Sparks RG.
Author information
1
Department of Pharmacology, NeuroSearch A/S, 93 Pederstrupvej, Ballerup, Denmark. [e-mail]
Abstract
Binding studies initially suggested that the muscarinic agonist, xanomeline, was a subtype selective muscarinic M(1) receptor agonist, and a potential new treatment for Alzheimer's disease. However, later in vitro and in vivo functional studies suggest that this compound is probably better described as a subtype selective M(1)/M(4) muscarinic receptor agonist. This subtype selectivity profile has been claimed to explain the limited classical cholinomimetic side effects, particularly gastrointestinal, seen with xanomeline in animals. However, in both healthy volunteers and Alzheimer's patients many of these side effects have been reported for xanomeline and in the patient population this led to a >50% discontinuation rate. Clearly, the preclinical studies have not been able to predict this adverse profile of xanomeline, and this suggests that either xanomeline is not as subtype selective as predicted from preclinical research or that there are differences between humans and animals with regard to muscarinic receptors. Nevertheless, in Alzheimer's patients xanomeline dose-dependently improves aspects of behavioral disturbance and social behavior including a reduction in hallucinations, agitation, delusions, vocal outbursts and suspiciousness. The effects on cognition are not as robust and mainly seen at the highest doses tested. These effects in Alzheimer's patients have given impetus to the suggestion that muscarinic agonists have potential antipsychotic effects. The current review assesses the antipsychotic profile of xanomeline within the framework of the limited clinical studies with cholinergic agents in man, and the preclinical research on xanomeline using various models commonly used for the assessment of new antipsychotic drugs. In general, xanomeline has an antipsychotic-like profile in various dopamine models of psychosis and this agrees with the known interactions between the cholinergic and dopaminergic systems in the brain. Moreover, current data suggests that the actions of xanomeline at the M(4) muscarinic receptor subtype might mediate its antidopaminergic effects. Particularly intriguing are studies showing that xanomeline, even after acute administration, selectively inhibits the firing of mesolimbic dopamine cells relative to dopamine cell bodies projecting to the striatum. This data suggest that xanomeline would have a faster onset of action compared to current antipsychotics and would not induce extrapyramidal side effects. The preclinical data on the whole are promising for an antipsychotic-like profile. If in a new formulation (i.e., transdermal) xanomeline has less adverse effects, this drug may be valuable in the treatment of patients with psychosis.

PMID: 12847557 PMCID: PMC6741650 DOI: 10.1111/j.1527-3458.2003.tb00247.x

Link to full paper:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741650/

[XenaLives]

A picture is worth a thousand words..



https://fintel.io/so/us/krtx

[Taurus69]

$krtx https://karunatx.com/

[Taurus69]

$krtx Share Structure

Market Cap Market Cap
2,247,624,384
11/18/2019
Authorized Shares
Not Available
Outstanding Shares
23,412,754
08/08/2019

[Taurus69]

$krtx contact
33 Arch Street
Suite 3110
Boston, MA 02110
[phone]

[Taurus69]

$krtx $96

[TheFinalCD]

there about a quarter-million dollars on ask @ $90

imagine being short 2500 shares, then tomorrow it opens @ offering

[TheFinalCD]

a-n-o-m-@-l-y

[TheFinalCD]

how in the world is it still holding


usually market tanks on offering news


this is really weird

[no shorts]

Offering is all the way back down at 17. They do not trade options. I wanted to get some puts for the pull back but no luck

[ClayTrader]

* * $KRTX Video Chart 11-18-19 * *

Link to Video - click here to watch the technical chart video

[VMB-1]

Haha I was waiting for an Offering!.. Typical

[Pyramid2]

So you have traded more than me can you explain to me how they can do a $17.38 offering of 2,600,000 shares AH and it is still $80 plus with phase II only results, ah, insane strength it will not roll over?

[cjstocksup]

As I said they would run KRTX to $100.00 and they did. I got out just under but congrats to all who held for that. It seemed obvious to me since premarket and the first hour of trading action it would happen.

[Nebuchadnezzar]

KRTX $100 hit surges up 450%

ludicrous

a lot of people are closer to retirement today.

damn

[VMB-1]

~Either Crashn Harddd or Hitting 125 EOD

[Actualfactual]

Just waiting for a dip...any dip..any time now

[Actualfactual]

Wow. Going to hit 100..

[VMB-1]

~100 Pop Coming... Might hit PT...Today

LMAOOO.. Wish I held it

[Actualfactual]

It’s RSI is like 99.9 right now..

[VMB-1]

~Sickkkkk I sold around 10.30 Never even Dipped Hard, Congrats..they usually don't do this!

[Actualfactual]

Citi just raised pt to $115 from $29. But I ain’t touching this super overbought thing at low $80’s. It’s gonna reset at some point soon.

[cjstocksup]

Really? Nice steady stair step today and $75.00 HOD so far. Longs are winning.

No way.

[cjstocksup]

$75.00 so far. It will get interesting. I would not be surprised if they try to run it $100.00. I am so happy with my KRTX returns so far either way.

~Volume is dissipating..I wouldnt bet on it.. But still early...

[rynlrt]

Wow. Shorts are gonna eat this up this week

[XenaLives]

They have competition that is much further along IMO..

ANAVEX2-73 is an experimental drug is in Phase II trials for Alzheimer’s disease, phase I trials for epilepsy, and in preclinical trials for amyotrophic lateral sclerosis, Parkinson’s disease, Rett syndrome, stroke.[1][2] ANAVEX2-73 acts as a muscarinic receptor and a moderate sigma1 receptor agonist.[1] ANAVEX2-73 may function as a pro-drug for ANAVEX19-144 as well as a drug itself. ANAVEX19-144 is the active metabolite of ANAVEX 1-41, which is similar to ANAVEX2-73 but it is not as selective for sigma receptor.[2]

https://newdrugapprovals.org/tag/blarcamesine/

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152296122&txt2find=Muscarinic

[XenaLives]

quick Google for background:

Karuna Therapeutics Readies Plan For $70 Million IPO ...
https://seekingalpha.com › article › 4271532-karuna-therapeutics-readies-p...
Jun 21, 2019 - Karuna Therapeutics (KRTX) has filed to raise gross proceeds of up to $70 million from a US IPO, according to an S-1/A registration statement.
Karuna Therapeutics' (KRTX) IPO Opens at $18.50 After ...
https://www.streetinsider.com › IPOs › Karuna+Therapeutics+(KRTX)+IPO...
Jun 28, 2019 - Karuna Therapeutics, Inc.'s (NASDAQ: KRTX) IPO opened for trading at $18.50 after pricing 5,578,124 shares of common stock at a public ...
Karuna Therapeutics, Inc. Common Stock (KRTX) Latest ...
https://www.nasdaq.com › Market Activity › Stocks
Find the latest quotes for (Karuna Therapeutics, Inc. Common Stock) (KRTX) as well ... Latest Headline Schizophrenia biotech Karuna Therapeutics prices IPO at ...
Market Cap?: ?328,012,684 Previous Close?: ?$14.82
Volume?: ?63,243
Karuna Therapeutics Announces Closing of Initial Public ...
https://www.businesswire.com › news › home › Karuna-Therapeutics-Ann...
Jul 2, 2019 - Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage ... today announced the closing of its initial public offering of 6,414,842 shares of ...
Karuna Therapeutics Opens Above IPO Price - Benzinga
https://www.benzinga.com › news › karuna-therapeutics-opens-above-ipo-...
Jun 28, 2019 - Karuna Therapeutics, Inc. (NASDAQ: KRTX) made its public debut Friday morning, opening at $18.50 after being priced at $16 per share.

[XenaLives]

Daily volume jump is absurd, my guess would be VC cashing in some chips:

 
 11/18/19	32.50	67.48	32.47	65.36	6,022,411 
 11/15/19	17.39	17.9499	16.80	17.68	60,050 
 11/14/19	17.75	18.61	17.21	17.39	79,418 
 11/13/19	16.61	18.255	16.34	17.65	70,171 
 11/12/19	17.17	17.48	16.7016	17.01	59,356 
 11/11/19	17.74	18.15	17.065	17.25	51,973 
 11/08/19	17.80	18.835	17.46	17.79	62,658 
 11/07/19	17.52	18.38	16.545	17.76	66,790 
 11/06/19	17.51	19.20	16.78	17.05	148,978 
 11/05/19	15.64	17.98	15.12	17.30	94,038 
 11/04/19	15.24	15.95	15.01	15.59	34,693 
 11/01/19	14.04	15.33	13.52	15.15	74,803 
 10/31/19	13.77	14.15	13.29	13.92	41,307 
 10/30/19	12.77	13.97	12.64	13.73	50,605 
 10/29/19	13.82	14.79	12.48	12.77	107,728 
 10/28/19	13.94	14.15	13.375	13.82	55,279 
 10/25/19	14.04	14.89	13.515	14.55	59,723 
 10/24/19	14.50	14.65	13.775	13.98	61,898 
 10/23/19	14.01	15.25	13.605	14.44	83,196 
 10/22/19	14.72	15.20	13.10	14.01	88,520 
 10/21/19	15.76	17.0486	14.19	14.82	78,549 
 10/18/19	13.31	15.92	13.31	15.58	58,352 
 10/17/19	13.41	13.91	12.98	13.29	118,364 
  
 

[XenaLives]

Overall, KarXT was well tolerated in the clinical trial, with similar discontinuation rates of patients on KarXT, 20%, and placebo, 21%. The number of discontinuations due to treatment emergent AEs were equal in the KarXT and placebo arms (N=2 in each group). The overall AE rate of patients on KarXT was 54% vs. 43% on placebo, with the most common AEs being constipation, nausea, dry mouth, dyspepsia, and vomiting. The tolerability of KarXT was also reflected in the trial’s high rate of dose escalation. In the trial, 91% of KarXT treated patients escalated to the increased dose which was similar to the escalation rate with placebo. Occurrences of somnolence, weight gain, and extrapyramidal symptoms were also similar to placebo. One serious adverse event (SAE) was experienced in the drug treatment arm, in which the patient discontinued treatment and subsequently sought hospital care for worsening psychosis, meeting the regulatory definition of an SAE.

“The schizophrenia treatment landscape has remained rather stagnant for decades with therapeutic options relying on discoveries dating back to the 1950s,” said Steve Paul, M.D., chief executive officer, president, and chairman of Karuna. “KarXT and its novel muscarinic receptor mechanism of action represent the potential to become a true advancement in how schizophrenia is treated, allowing patients relief from their debilitating psychotic symptoms without experiencing some of the very troubling side effects associated with current treatments.”

Muscarinic acetylcholine receptors emerged in the 1990s as a promising alternative target to dopamine-receptor based treatments for treating psychosis, but adverse side effects limited their development as a therapeutic option. It is believed that these side effects were the result of the stimulation of muscarinic receptors in peripheral tissues. Karuna addressed this issue by combining xanomeline, a novel muscarinic receptor agonist that preferentially stimulates M1 and M4 muscarinic receptors, with trospium, an approved muscarinic receptor antagonist that does not measurably cross the blood-brain barrier, confining its effects to peripheral tissues. The resulting therapeutic, known as KarXT, was designed to activate muscarinic receptors in the CNS while avoiding the side effects associated with activating muscarinic receptors in peripheral tissues.

https://ih.advfn.com/stock-market/NASDAQ/karuna-therapeutics-KRTX/stock-news/81163868/karuna-therapeutics-announces-karxt-met-primary-en

[Actualfactual]

Exactly. This price is just stooopid. I’ll wait for stop loss raid..